<DOC>
	<DOCNO>NCT00095173</DOCNO>
	<brief_summary>The primary purpose clinical research study assess safety treat child juvenile subject BMS-188667 ( Abatacept ) . In addition , study assess effectiveness BMS-188667 reduce disease activity Juvenile Rheumatoid Arthritis ( JRA ) Juvenile Idiopathic Arthritis ( JIA ) measure time occurrence disease flare .</brief_summary>
	<brief_title>BMS-188667 Children Adolescents With Juvenile Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis Juvenile Rheumatoid Arthritis Juvenile Idiopathic Arthritis ; Current active arthritis ; Failed treatment least one disease modify antirheumatic drug ( DMARD ) ; Subjects must discontinue use DMARD methotrexate prior first dose study medication Presence infection history frequent acute chronic infection ; Joint replacement surgery require study history surgery 5 joint ; Live vaccine within 3 month first dose study medication ; Unresolved serious bacterial infection chronic bacterial infection ; Subjects currently intermittent fever due JRA/JIA , rheumatoid rash , hepatosplenomegaly , pleuritis , pericarditis , macrophage activation syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Juvenile Idiopathic Arthritis</keyword>
</DOC>